Powder: -20°C for 3 years | In solvent: -80°C for 1 year
AGI-14100 is a novel and orally available mIDH1 inhibitor.AGI-14100 is used for the treatment of primary human myeloid leukemia.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 350.00 | |
5 mg | In stock | $ 828.00 | |
10 mg | In stock | $ 1,130.00 | |
25 mg | In stock | $ 1,590.00 | |
50 mg | In stock | $ 1,980.00 | |
100 mg | In stock | $ 2,500.00 |
Description | AGI-14100 is a novel and orally available mIDH1 inhibitor.AGI-14100 is used for the treatment of primary human myeloid leukemia. |
Targets&IC50 | IDH1-R132H homodimer (mutation):6 nM, HT1080 (chondrosarcoma cell lines):1 nM |
In vivo |
AGI-14100 (50 mg/kg; oral; single; female nude BALB/c mice) inhibition robust tumor 2-HG was achieved 12 hours post-dose demonstrating desirable in vivo results.[1] AGI-14100 had decent oral pharmacokinetics (PK) properties in rats (F =44 %), dogs (F =18 %), and cynomolgus monkeys (F =43 %).[1] |
Synonyms | AGI 14100 |
Molecular Weight | 599.96 |
Formula | C29H22ClF4N5O3 |
CAS No. | 1448346-43-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (83.34 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
AGI-14100 1448346-43-7 Metabolism Dehydrogenase AGI 14100 AGI14100 inhibitor inhibit